Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 8;16(1):1507.
doi: 10.1007/s12672-025-03369-3.

Multi-omics insights into Palmitoylation-mediated brain network remodeling and glioblastoma risk

Affiliations

Multi-omics insights into Palmitoylation-mediated brain network remodeling and glioblastoma risk

Shasha Tan et al. Discov Oncol. .

Abstract

Glioblastoma (GBM) remains a lethal brain tumor with limited therapeutic progress, necessitating novel insights into its molecular drivers. This study investigates the causal role of protein palmitoylation-a post-translational modification regulating tumor metabolism and microenvironment-in GBM pathogenesis through neuroimaging-mediated pathways. Leveraging two-sample Mendelian randomization (MR) and multi-omics data from FinnGen (406 GBM cases/378,749 controls) and UK Biobank (3,935 brain imaging phenotypes), we identified protective effects of palmitoylation-related genes (ZDHHC3: OR = 0.17, 95%CI = 0.0602–0.4824; ZDHHC6: OR = 0.41, 0.2330–0.7267; ZDHHC13: OR = 0.64, 0.4745–0.8618; PPT2: OR = 0.59, 0.3568–0.9843) against GBM risk. Neuroimaging mediation analysis revealed that 15–23% of this protection operates through structural and functional brain remodeling, including reduced parahippocampal volume (mediated 15.96% for ZDHHC13), diminished default mode network connectivity ICA100 edge 295, and ICVF Body of corpus callosum(15.29% mediation for ZDHHC6). Bidirectional regulation was observed in motor pathways, where palmitoylation genes simultaneously suppressed corticospinal tract integrity (FA) and enhanced cortical plasticity. Sensitivity analyses confirmed robustness (Cochran’s Q p > 0.05; MR-PRESSO global test p > 0.05), with Steiger filtering excluding reverse causation. Our findings suggest that palmitoylation may play a key modulatory role in GBM risk through influencing brain network dynamics, highlighting neuroimaging features (e.g., DMN connectivity, parahippocampal atrophy) as potentially informative for GBM risk and warranting further investigation for their role in early detection. These results also raise the possibility of palmitoylation-targeted therapies aimed at disrupting tumor-microenvironment crosstalk, suggesting a direction for future therapeutic exploration.

Supplementary Information: The online version contains supplementary material available at 10.1007/s12672-025-03369-3.

Keywords: Brain network remodeling; Glioblastoma; Multi-omics; Neuroimaging endophenotypes; Palmitoylation; Protective mechanism.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval and consent to participate: Not available. Consent for publication: All authors reviewed and approved the final manuscript. Competing interests: The authors declare no competing interests. Clinical trial number: Not applicable.

Figures

Fig. 1
Fig. 1
Presents our analytical framework for studying the role of protein palmitoylation in glioma development. It mainly includes: (1) Mendelian randomization analysis, evaluating the direct causal effects of genetically predicted palmitoylation on GBM risk; (2) Mediation analysis, examining the role of neuroimaging endophenotypes and palmitoylation as mediators; (3) Sensitivity analysis, ensuring the reliability of the results. Color-coded pathways represent different mechanisms of action
Fig. 2
Fig. 2
Mendelian randomization analysis of the relationship between Palmitoylation and GBM

Similar articles

References

    1. Batash R, Asna N, Schaffer P, et al. Glioblastoma multiforme, diagnosis and treatment; recent literature review. Curr Med Chem. 2017;24(27):3002–9. 10.2174/0929867324666170516123206. - PubMed
    1. Tamimi AF, Juweid M. Epidemiology and outcome of glioblastoma. De Vleeschouwer S. Glioblastoma. Brisbane (AU): Codon Publications; 2017. - PubMed
    1. Pouyan A, Ghorbanlo M, Eslami M, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24:58. 10.1186/s12943-025-02267-0. - PMC - PubMed
    1. Sattiraju A, Mintz A. Pericytes in glioblastomas: multifaceted role within tumor microenvironments and potential for therapeutic interventions. Adv Exp Med Biol. 2019;1147:65–91. 10.1007/978-3-030-16908-4_2. - PMC - PubMed
    1. Kumari S, Gupta R, Ambasta RK, et al. Emerging trends in post-translational modification: shedding light on Glioblastoma multiforme. Biochimica et Biophysica Acta (BBA). 2023;1878(6): 188999. 10.1016/j.bbcan.2023.188999. - PubMed

LinkOut - more resources